Browsing ICR Divisions by author "Shum, Ben"
Now showing items 1-7 of 7
-
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
Gudd, CLC; Au, L; Triantafyllou, E; Shum, B; Liu, T; et al. (ELSEVIER, 2021-07-01)BACKGROUND & AIMS: Checkpoint inhibitor-related hepatitis (CPI-Hep) is an emerging clinical challenge. We aimed to gain insights into the immunopathology of CPI-Hep by comprehensively characterising myeloid and lymphoid ... -
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27)Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients ... -
Exploring mechanisms of response and resistance to immuno-oncology approaches in melanoma
Turajlic S; Shum, B; Turajlic, S (Institute of Cancer Research (University Of London), 2024-05-21)Background Immuno-oncology strategies have transformed the prognosis of advanced melanoma; in particular, immune checkpoint inhibitors (ICIs) provide durable response in a subset of patients, while tebentafusp (tebe) is ... -
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Fendler, A; Au, L; Shepherd, STC; Byrne, F; Cerrone, M; et al. (NATURE PORTFOLIO, 2021-09-20)Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were ... -
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Fendler, A; Shepherd, STC; Au, L; Wu, M; Harvey, R; et al. (CELL PRESS, 2022-10-18)Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we ... -
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
Spain, L; Coulton, A; Lobon, I; Rowan, A; Schnidrig, D; et al. (AMER ASSOC CANCER RESEARCH, 2023-06-02)UNLABELLED: Understanding the evolutionary pathways to metastasis and resistance to immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present the most comprehensive intrapatient ... -
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.
Wu, MY; Shepherd, STC; Fendler, A; Carr, EJ; Au, L; et al. (CELL PRESS, 2023-05-08)Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.